

### France HADRON

a national infrastructure for hadrontherapy research including ETOILE, ARCHADE and protontherapy centers

Jacques BALOSSO, MD, PhD

University Joseph Fourier, Grenoble 1

Jean Louis HABRAND, MD, PhD

University of Caen, Centre François Baclesse and IGR Coordinators of France HADRON



#### **Context and challenges**

- The cancer treatments based on physical approaches remain necessary because of tumor heterogeneity
- Carbon ion therapy is a reliable and relatively cheap treatment of unresectable and radioresistant tumors
- It is a **new domain of medical technology** where France could have input in R&D and economical development
- French research in hadrontherapy has gain and international visibility that worth to be supported
- A need **to federate this multidisciplinary domain** with multiple locations of the involved teams
- The next "plan cancer" (2014-2019) propose a "national regulation for expensive facilities <u>as for example</u> protontherapy facilities"







#### A bit of history (1)

#### The France HADRON infrastructure is based on a large heritage:

- The sites of Caen (GANIL), Nice (Médicyc) and Orsay (ICPO) are existing for more than 20 years...
- A Regional program for hadrontherapy research (PRRH) has been initiated in 2002 in Lyon just after the announcement of the carbon ion project in 1997, named ETOILE
- The CNRS launched the Mi2b GDR, end of 2004
- Caen presented its own project, Asclépios, in 2005
- A first attempt of national program in 2007 did not succeed (opposition of the INCa...)







#### A bit of history (2)

- **Projects** for new centers or upgrade of existing centers are existing for both carbon ions and protons: at Lyon (ETOILE), Caen (Archade), Orsay (2010), Nice (2014) and more, Toulouse, Nantes, Lyon for protons.
- Since 2001 the French teams have effective links with the CERN, GSI, CNAO, MedAustron and the NIRS. Moreover, they have actively participated to every **European consortia** and research programs as: Enlight (2001-...), Enlight++, ULICE (2009-14), ENVISION, Partner (2010-13), Intervision.
- **Teams from other towns** than those having project of centers are joining and actively participating, mainly through CNRS teams: Clermont-Ferrand, Marseille, Strasbourg, Grenoble... totalizing more than twenty research teams all over France.
- Hadrontherapy research is thus active in France for more than twenty years **\*\* ICTR-PHE \*\*\* 2014**





#### Difficulties to overdraw

- The spreading of the material and teams
- The deep lack of access to the beams, which are either:
  - In medical centers with few research infrastructure (Nice, Orsay)
  - Or in research centers which agenda is not specifically devoted to hadrontherapiy (GANIL)
- A weak industrial and governmental support in France although a very high know how in research institution (IN2P3, CEA) and some well known small corporations (Pantechnic, Sigmaphi)
- The lack of referent carbon ion center in France
- And the lack of controlled randomized comparative clinical studies in the domain of hadrontherapy although 27 years of neutrontherapy and 22 years of protontherapy in France (circa 10000 patients, 50% having ocular tumours)







#### The opportunity of the « Grand Emprunt » in 2010

- The French government launched a huge call for projects in 2010 and 2011 for boosting research and training in any domain important for the economical welfare and development in the future.
- Different forms of complementary responses could be proposed: **Equipex, Labex, National Infrastructures**.
- The proposals were evaluated by **international boards**.
- Hadrontherapy has been rather successful in that game obtaining recognition from three independent international boards for 1 Equipex in Caen, 1 Labex in Lyon and 1 National Infrastructure: France HADRON.







#### France HADRON - objectives

- To <u>federate</u> research teams and organize research at a national level,
- To fund beam time and beam line access for research.
- To <u>open</u> new research beam lines for protons and carbon ions, to increase available beam time
- To optimize technical means and procedure for hadrontherapy,
- To <u>network</u> in the frame of the European programs
- To have a <u>positive input</u> on economy







## France HADRON is a unique national institution made of 5 centers

- A national infrastructure distributed on 5 nodes (places):
  - ETOILE Center in Lyon,
  - ARCHADE Center in Caen,
  - Centre Antoine Lacassagne / IMPACT in Nice,
  - Curie Institute / ICPO in Orsay,
  - Claudius Regaud Institute / PERICLES in Toulouse.
- with the partnership of CNRS/IN2P3 (IPNL & LPC) and of IRSN,
- and the support of INSERM, INCa, CEA, ENLIGHT, ULICE and 16 industrials and public institutions including CNES, Thales,
   Mérieux, AREVA, ...







#### France HADRON - scientific project (1)

- Multidisciplinary: medicine, physics, biology, computer, etc.
- 25 teams are involved :
  - <u>Lyon Clermont-Fd</u>: teams of C. Rodriguez-Lafrasse, M. Beuve, D. Dauvergne, G Montarou, N. Foray, D. Sarrut, B. Shariat, B. Ribba, P. Pommier.
  - Nice: teams of JM. Hannoun-Levi, P. Mandrillon.
  - Orsay: teams of A. Fourquet / R. Dendale, A. Mazal, J. Hall / F. Pouzoulet.
  - <u>Caen</u>: teams of D Cussol / J. Colin, M. Bernaudin, K. Boumediène, JL. Lefaix, MH. Moscatello, JL. Habrand.
  - <u>Toulouse</u>: teams of E. Moyal, P. Celsis / A. Laprie / M. Delannes, R. Ferrand







#### France HADRON - scientific project (2)

- Organized into 4 working packages:
  - WP1 How to identify and assess the medical value of hadron therapy (clinical research); Jean Louis HABRAND (Caen-Paris)
  - WP2 How to improve treatment plans (measurements, modeling and computer simulation); Daniel CUSSOL (Caen)
  - WP3 How to better understand the effect of treatment (radiation biology, radiotoxicology); Claire RODRIGUEZ-LAFRASSE (Lyon)
  - WP4 How to improve the quality control of treatment (instrumentation);
     Denis DAUVERGNE (Lyon).







### France HADRON - scientific project (3)



#### France HADRON - governance

National Agency for research (ANR) and CNRS for management (DR19 in Caen) France HADRON **Coordinators: Jacques Balosso** & JL Habrand (3 years mandate) Assistance (2 persons) **Steering Committee (SC/CD)** (President **Gérard Montarou**, 3 years Scientific mandate) **Executive Management Committee / Advisory** - IN2P3 representative **Experience Committee (MC/CG) Board (SAB)** - ITMO TS representative (monthly meeting) - ITMO Cancer representative (President Régis Férrand, 2 years (annual meeting) - Partners and Node mandate) representatives - Node representatives - Scientific representative of - WP leaders territorial Councils - Regional representatives of Minister of science (DRRT)

# France HADRON received 15 M€ for 2013-2019 principal support

The provisional distribution is the following:

- 5495,60 k€ for the general activities, the <u>beam</u> access cost and the clinical research support
- 5900,00 k€ for equipments to make possible new and easier beam access: 5 M€ for proton in Nice and Orsay and 0,9 M€ for carbon at GANIL
- 3604,40 k€ are kept as a reserve for future developments possibly for carbon ions.








#### France HADRON - prospect


The financial starting point is 1<sup>st</sup> of March 2013, the financial agreement has been signed mid September 2013, the launching meeting took place in Meudon (near Paris) the 14<sup>th</sup> of October 2013

Recruitment of assistance staff is ongoing



15

# Global organization of hadrontherapy research in France around FrHA



#### **Conclusion and perspectives**

- Thanks to FrHA the hadrontherapy research domain is now unified and coordinated and should have continuity
- The main **innovative axe in carbon ion** therapy is the cooperation between: Caen Lyon
- In each location, and specifically in Lyon, the connection between the different organizations (Labex and Infrastructure) will have to be finely define and smoothly run together
- FrHA should also continue to participate actively to European programs in the frame of Horizon 2020
- The challenge to continue to integrate new facilities (protons?)
   and new teams coming into that research domain is open
- The new "Plan cancer" remains open to hadrontherapy, however no governmental decision toward ETOILE project has been done yet...







## Rhôn€√lpes





## Thank-you











